GLP-1 Benefits Beyond Weight Loss: What’s Proven, and What’s Still a Maybe?

GLP-1 medicines are often discussed as weight-loss drugs, but research now covers a wider set of health outcomes. Some benefits are supported by large trials and specific regulatory approvals. Others are early signals that need more evidence.

The key detail: benefits are not interchangeable across every medicine in the GLP-1 family. They depend on the drug, condition, population studied and local product label.

Heart health: a major change in the story

In March 2024, the US FDA approved a cardiovascular risk-reduction indication for Wegovy (semaglutide) in adults with established cardiovascular disease and overweight or obesity. The supporting SELECT trial enrolled more than 17,600 participants. Major adverse cardiovascular events occurred in 6.5% of the Wegovy group and 8.0% of the placebo group during the trial.

That is a result for a defined population and a particular product and indication. It should not be rewritten as “all GLP-1 medicines prevent heart attacks in everyone.”

Mounjaro gained a US indication in August 2026 to lower major cardiovascular events in adults with type 2 diabetes at high risk, based on a trial showing it was non-inferior to dulaglutide.

Sleep apnea: a specific tirzepatide indication

The FDA approved Zepbound (tirzepatide) in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside reduced-calorie eating and increased physical activity. In the SURMOUNT-OSA trials, tirzepatide improved sleep-apnea severity and other measures in the studied population.

This does not mean the medicine replaces an individual's sleep-apnea care or that all snoring is sleep apnea. Diagnosis and treatment choices belong with a healthcare professional.

Heart failure: evidence from the SUMMIT trial

In the SUMMIT trial, tirzepatide was studied in people with obesity and heart failure with preserved ejection fraction (HFpEF). The trial found a reduction in a composite of cardiovascular death or worsening heart-failure events compared with placebo, alongside improvement in health status. This is a specific result in a specific population—not a general heart-protection guarantee for everyone using tirzepatide.

Heart failure with preserved ejection fraction is not an FDA-approved indication for tirzepatide; Lilly withdrew its US application in 2025 after the FDA requested an additional trial.

Kidney disease: semaglutide in people with type 2 diabetes and CKD

The FLOW trial studied semaglutide in people with type 2 diabetes and chronic kidney disease. It found a reduction in the trial's composite kidney/cardiovascular outcome. The result concerns a defined, high-risk population rather than a claim that semaglutide improves every person's kidney health.

Based on FLOW, the FDA approved this kidney indication for Ozempic in January 2025.

Fatty liver (MASH) and other cardiometabolic outcomes

Wegovy (semaglutide 2.4 mg) received FDA accelerated approval in August 2025 for adults with MASH (metabolic dysfunction-associated steatohepatitis) and moderate-to-advanced liver fibrosis (F2–F3) without cirrhosis, based on liver-biopsy improvements in the ESSENCE trial; a confirmatory trial is ongoing. For tirzepatide, MASH remains under study, along with blood pressure, lipid markers, inflammation and body composition. A 2026 meta-analysis of 17 tirzepatide trials reported favourable results across several domains; the authors cautioned that the heart-failure and MASH findings rest on few trials.

An improved lab marker is not always the same thing as a proven long-term clinical benefit. It helps to know what a study measured, who was enrolled and whether results changed an official indication.

Alcohol cravings, PCOS and other “could it help?” questions

Researchers are exploring whether effects on appetite and reward pathways may matter beyond body weight. For alcohol use disorder, a 2025 review described a mix of preclinical, observational and early clinical evidence, with trials ongoing. The evidence is not enough to present GLP-1 medicines as an established treatment for alcohol use disorder.

Studies of GLP-1 drugs in PCOS are also developing, but available trials have limitations, including small samples and short durations. Do not imply a medicine is approved to treat PCOS or fertility problems unless the current regulator label says so.

How to read a “miracle benefit” headline

Ask four questions:

1. Was this a randomized clinical trial, observational association, animal study or patient anecdote?
2. Which exact medicine was studied?
3. Who was eligible, and how long were they followed?
4. Is the claim on an official label, or is it still being studied?

The takeaway

There are important findings beyond the scale—but the details matter. Several of these findings are FDA-approved for specific products and populations (heart, sleep apnea, kidney, MASH); the heart-failure finding is trial evidence without a US indication. Other possible benefits should remain in the “being studied” category until the evidence supports stronger conclusions.

GLPily helps people organize weight trends, injections and symptoms, but it does not determine whether a medicine is appropriate or provide medical treatment.